跳至內容

貝凡洛爾

維基百科,自由的百科全書
貝凡洛爾
臨床資料
AHFS/Drugs.com國際藥品名稱
給藥途徑口服
ATC碼
識別資訊
  • (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
CAS號59170-23-9  checkY
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C20H27NO4
摩爾質量345.44 g·mol−1
3D模型(JSmol英語JSmol
手性外消旋混合物
  • O(c1ccc(cc1OC)CCNCC(O)COc2cc(ccc2)C)C
  • InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3 checkY
  • Key:HXLAFSUPPDYFEO-UHFFFAOYSA-N checkY

貝凡洛爾INN:Bevantolol)是一種治療心絞痛高血壓的候選藥物,可作為β受體阻滯劑鈣通道阻滯劑[1][2]它是由華納-蘭伯特發現和開發的,[3]但在1989年1月,該公司宣布已撤回新藥申請;公司董事長說:「誰需要第30個β受體阻滯劑?」[4]截至2016年,它沒有在美國英國歐洲上市,考科藍評論的作者找不到它的產品專論。[5]

參考資料

  1. ^ Frishman WH, Goldberg RJ, Benfield P. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. January 1988, 35 (1): 1–21. PMID 2894292. doi:10.2165/00003495-198835010-00001. 
  2. ^ Vaughan Williams EM. Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. Journal of Clinical Pharmacology. July 1987, 27 (7): 450–60. PMID 2888789. S2CID 72749127. doi:10.1002/j.1552-4604.1987.tb03049.x. 
  3. ^ McPherson EM. Pharmaceutical Manufacturing Encyclopedia. 3rd. Burlington: Elsevier. 2007: 618–619. ISBN 9780815518563. 
  4. ^ Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds. Pink Sheet. 30 January 1989 [2023-04-08]. (原始內容存檔於2016-11-27). 
  5. ^ Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. The Cochrane Database of Systematic Reviews. March 2016, 3 (4): CD007451. PMC 6486283可免費查閱. PMID 26961574. doi:10.1002/14651858.CD007451.pub2.